ACLY and lung adenocarcinoma: The ACLY inhibitor SB-204990 has been set out to inhibit the proliferation of lung adenocarcinoma cells in vivo and in vitro. Other ACLY inhibitors like difluorocitric acid and hydroxycitrate have been demonstrated to block the synthesis of FAs.